Results of Operations and Financial Condition On August 11, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…

Entry into a Material Definitive Agreement On June 30, 2026, Neurogene Inc. (the “Company”) entered into an underwriting agreement (the “Underwriting Agreement”) with Leerink Partners LLC, Stifel, Nicolaus & Company, Incorporated, and Guggenheim Securities, LLC, as representatives of the underwriters named therein (the “Underwriters”), to issue and sell 3,500,000 shares of the Company’s common stock at a public offering price of $30.00 per share and, in lieu of common stock to certain investo…

Results of Operations and Financial Condition On May 12, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2026. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on May 12, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The…

Director — Christine Mikail: Christine Mikail, the President and Chief Financial Officer of Neurogene Inc., was appointed as a Class II director.

Results of Operations and Financial Condition On March 24, 2026, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2026, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report o…

Results of Operations and Financial Condition On November 13, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended September 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on November 13, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on…

Results of Operations and Financial Condition On August 11, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2025. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 11, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K.…

The filing pertains to amendments of equity and stock purchase plans, not a management change.

and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

Entry Into a Material Agreement Amendment to Letter Agreement On April 14, 2025, Neurogene Inc. (the “ Company ”) entered into an amendment to the July 17, 2023 letter agreement between the Company and Baker Bros. Advisors LP and/or one or more of its affiliates (collectively, “ BBA ”), pursuant to which the parties agreed to increase the threshold at which BBA has certain rights to nominate one person for election as a director of the Company from a minimum of 12.5% of the Company’s then-out…

Results of Operations and Financial Condition On March 24, 2025, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter and year ended December 31, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on March 24, 2025, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report o…

and Exhibit 99.1 attached hereto are being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall such information or Exhibit 99.1 be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

Based in part upon the representations of the Purchasers in the Securities Purchase Agreement, the offering and sale of the securities will be made in reliance on the exemption afforded by Section 4(a)(2) of the Securities Act and/or Regulation D thereunder, and corresponding provisions of state securities or “blue sky” laws. The securities will not be registered under the Securities Act or any state securities laws and may not be offered or sold in the United States absent registration with…

of this Current Report on Form 8-K, including the information in the press release attached as Exhibit 99.1 to this Current Report on Form 8-K, shall not be deemed to be incorporated by reference in the filings of the Company under the Securities Act. Forward-Looking Statements This Current Report on Form 8-K contains “forward-looking statements” within the meaning of Section 27A of the Securities Act and Section 21E of the Exchange Act. These statements may discuss goals, intentions and expe…

Entry Into a Material Agreement Securities Purchase Agreement On November 4, 2024, Neurogene Inc., a Delaware corporation (the “ Company ”), entered into a securities purchase agreement (the “ Securities Purchase Agreement ”) with certain institutional accredited investors named therein (each, a “ Purchaser ” and collectively, the “ Purchasers ”), pursuant to which the Company agreed to issue and sell to the Purchasers in a private placement (the “ Private Placement ”) (i) an aggregate of 1,8…

Results of Operations and Financial Condition On August 9, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended June 30, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on August 9, 2024, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. T…

Results of Operations and Financial Condition On May 10, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the quarter ended March 31, 2024. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. Also on May 10, 2024, the Company posted an updated corporate presentation on its website. A copy of the corporate presentation is furnished as Exhibit 99.2 to this Current Report on Form 8-K. The…

Chief Scientific Officer — Stuart Cobb, Ph.D.: The agreement updates the terms of Dr. Cobb's consulting services and compensation.

The filing details new employment agreements for the CEO and CFO, outlining their compensation and severance terms.

Results of Operations and Financial Condition On March 18, 2024, Neurogene Inc. (the “Company”) issued a press release announcing financial results for the year ended December 31, 2023. A copy of the press release announcing such results is attached as Exhibit 99.1 to this Current Report on Form 8-K. The information in this

and Exhibit 99.1 attached hereto is being furnished and shall not be deemed “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the "Exchange Act"), or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference into any filing under the Exchange Act or the Securities Act of 1933, as amended, except as expressly set forth by specific reference to such filing.

Senior Vice President, General Counsel — Donna Cochener: Ms. Cochener was appointed as Senior Vice President, General Counsel.